{
  "id": "TNM_Breast_Assessment.v1",
  "gdl_version": "2.0",
  "concept": "gt0001",
  "language": {
    "original_language": "ISO_639-1::en"
  },
  "description": {
    "original_author": {
      "date": "2016-06-18",
      "name": "Syeeda S Farruque",
      "organisation": "Cambio Healthcare Systems",
      "email": "syeeda.farruque@cambiocds.com"
    },
    "other_contributors": [
      "Dennis Forslund, Cambio Healthcare Systems"
    ],
    "lifecycle_state": "Author draft",
    "details": {
      "sv": {
        "id": "sv",
        "purpose": "American Joint Committee on Cancers (AJCC) TNM-klassifikation beskriver allvarlighetsgrad av bröstcancer baserat på tumörstorlek, lymfkörtelengagemang och förekomst av metastaser.",
        "keywords": [
          "TNM",
          "TNM-klassifikation",
          "bröstcancer",
          "cancer",
          "onkologi"
        ],
        "use": "Använd för stadieindelning av bröstcancer i enlighet med TNM-klassifikationen. Indelning sker efter kategori 0-4 med subgrupper inom respektive huvudkategori. Prognos uttrycks i 5-årsöverlevnad.\n \nStadium     5-årsöverlevnad           TNM                                 Beskrivning\t                                                                                                                          \n0                       99%                      \n                                                Tis N0 M0            Carcinoma in situ. Varken regionalt lymfkörtelengagemang eller fjärrmetastaser har kunnat påvisas.\n                                                                                                                                                     \nI                        92%\n                                                 T1 N0 M0           Tumör som störst 2 cm. Varken regionalt lymfkörtelengagemang eller fjärrmetastaser har kunnat påvisas.\n                                                                                                                                                                \nIIA                     82%\n                                                 T0 N1 M0            Primärtumör har ej kunnat fastställas. Metastaser i regionala lymfkörtlar ipsilateralt. Ingen fjärrmetastasering påvisad.\n                                                 T1 N1 M0            Tumören är som störst 2 cm. Metastaser i regionala lymfkörtlar ipsilateralt. Ingen fjärrmetastasering påvisad.\n                                                 T2 N0 M0            Tumören är 2-5 cm. Varken regionalt lymfkörtelengagemang eller fjärrmetastaser har kunnat påvisas.\n                                               \nIIB                      65%                         \n                                                  T2 N1 M0           Tumören är 2-5 cm. Metastaser i regionala lymfkörtlar ipsilateralt. Ingen fjärrmetastasering påvisad.                                                                                                               \n                                                  T3 N0 M0           Tumören är större än 5 cm. Varken regionalt lymfkörtelengagemang eller fjärrmetastaser har kunnat påvisas.\n                                                                             \t                                    \nIIIA                     47%                              \n                                                   T0 N2 M0          Primärtumör har ej kunnat fastställas. Metastaser i fixerade (icke rörliga) regionala lymfkörtlar ipsilateralt. Ingen fjärrmetastasering påvisad.\n                                                   T1 N2 M0          Tumören är som störst 2 cm. Metastaser i fixerade (icke rörliga) regionala lymfkörtlar ipsilateralt. Ingen fjärrmetastasering påvisad.\n                                                   T2 N2 M0          Tumören är 2-5 cm. Metastaser i fixerade (icke rörliga) regionala lymfkörtlar ipsilateralt. Ingen fjärrmetastasering påvisad.\n                                                   T3 N1-2 M0       Tumören är större än 5 cm. Metastaser i fixerade (icke rörliga) regionala lymfkörtlar ipsilateralt. Ingen fjärrmetastasering påvisad.\t\nIIIB                      44%                          \n                                                    T4 N1-3 M0      •Tumören har invaderat bröstväggen. Regionalt lymfkörtelengagemang. Inga fjärrmetastaser har kunnat påvisas.\n                                                    T1-4 N3 M0      •Oavsett tumörstorlek. Metastasering till ipsilaterala lymfkörtlar i bröstet.  Inga fjärrmetastaser har kunnat påvisas.\n        \t\nIV                        14%                       \n                                                    T1-4 N1-3 M1     Oavsett tumörstorlek eller grad av regionalt lymfkörtelengagemang. Fjärrmetastaser har påvisats.\t\n\n\n",
        "misuse": "TNM-klassifikation kräver data inhämtad med hjälp av högkvalitativa metoder inklusive bilddiagnostik och omfattande lymfkörtelundersökning. ",
        "copyright": "© Cambio Healthcare Systems"
      },
      "en": {
        "id": "en",
        "purpose": "The American Joint Committee on Cancer (AJCC) TNM staging system reports on the severity of breast cancer based on tumor, lymph node and metastasis characteristics. The characteristics of the size of the tumour, the extent of spread to local lymph nodes and body organs. These aspects are captured in 3 ways that make up the mnemonic TNM: T: Tumour size; N: Number of regional lymph nodes affected and M: whether the cancer has spread/metastasised beyond the primary organ and regional nodes. Each major category is further subdivided to help classify the picture further. These subdivisions are given suffixes or numbered as shown below.",
        "keywords": [
          "TNM breast cancer staging"
        ],
        "use": "There are main stages Stage 0 to IV with each stage (except Stage 0) subdivided. Survival rates are shown below:\n\nStage\tTNM\t            Description\t                                                                                                                 5-year Survival\n0\tTis N0 M0             Carcinoma in situ. \n                                                  No tumor is regional lymph nodes, No distant metastases\t                                                                      99%\nI\tT1 N0 M0\t            Tumor is less than or equal to 2 centimeters, \n                                                  No tumor in regional lymph nodes, No distant metastases                                                                                            92%\nIIA\tT0 N1 M0              No evidence of primary tumor, metastases to movable ipsilateral nodes, \n                   T1 N1 M0              No distant metastases.\n                   T2 N0 M0\t            Tumor is less than or equal to 2 centimeters, metastases to movable ipsilateral    \n                                                  nodes, No distant metastases.\n                                                 Tumor is between 2 and 5 centimeters, No tumor in regional lymph nodes,\n                                                 No distant metastases\t                                                                                                                                                      82%\nIIB\tT2 N1 M0             Tumor is between 2 and 5 centimeters, metastases to movable ipsilateral nodes,\n                   T3 N0 M0             No distant metastases.\n                                                 Tumor is over 5 centimeters, No tumor in regional lymph nodes, No distant metastases.\t                                      65%\nIIIA\tT0 N2 M0              No evidence of primary tumor, metastases to fixed ipsilateral nodes, no distant metastases.\n                   T1 N2 M0             Tumor is less than or equal to 2 centimeters, metastases to fixed ipsilateral nodes, No distant metastases.\n                   T2 N2 M0             Tumor is between 2 and 5 centimeters, metastases to fixed ipsilateral nodes, no distant metastases. \n                   T3 N1, N2 M0      Tumor is over 5 centimeters, metastases to movable or fixed ipsilateral nodes, no distant metastases.\t47%\nIIIB\tT4 Any N M0\nIIIC                        Any T N3 M0\tTumor extends to chest wall, any nodal involvement, no distant metastases.\n•\tAny primary tumor involvement, metastases to ipsilateral internal mammary nodes, no distant metastases.\t44%\nIV\tAny T Any N M1\tAny primary tumor involvement, any nodal involvement, distant metastases.\t14%\n",
        "misuse": "Using the TNM classification alone is not recommended in providing diagnostic assessment. Clinical evidence is required to back up the staging suggestions. ",
        "copyright": "© Cambio Healthcare Systems"
      }
    },
    "other_details": {
      "references": "Ref. 1: AJCC Cancer Staging Atlas A Companion to the Seventh Editions of the AJCC Cancer Staging Manual and Handbook\nCarolyn C. Compton David R Byrd; Julio Garcia-Aguilar; American Joint Committee on Cancer Content Provider. New York, NY : Springer New York : Imprint: Springer 2nd ed. 2012\n\nRef. 2: Theriault RL, Carlson RW, Allred C, et al. Breast Cancer, Version 3.2013: Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network : JNCCN. 2013;11(7):753-761.\n\nRef. 3: Regular updates for breast cancer staging and treeatment can be found on the NCCN  (National Comprehensive Cancer Network) website, accessed at: www.nccn.org\n\nRef. 4: Breast cancer survival rates: Cancer.org: https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/stages-of-breast-cancer.html"
    }
  },
  "definition": {
    "data_bindings": {
      "gt0002": {
        "id": "gt0002",
        "model_id": "openEHR-EHR-OBSERVATION.tnm_breast_cancer_staging.v1",
        "template_id": "openEHR-EHR-OBSERVATION.tnm_breast_cancer_staging.v1",
        "type": "INPUT",
        "elements": {
          "gt0007": {
            "id": "gt0007",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0007]"
          },
          "gt0020": {
            "id": "gt0020",
            "path": "/data/events/time"
          }
        },
        "predicates": [
          "max(/data/events/time)"
        ]
      },
      "gt0004": {
        "id": "gt0004",
        "model_id": "openEHR-EHR-EVALUATION.tnm_breast_cancer_assessment.v1",
        "template_id": "openEHR-EHR-EVALUATION.tnm_breast_cancer_assessment.v1",
        "type": "OUTPUT",
        "elements": {
          "gt0005": {
            "id": "gt0005",
            "path": "/data[at0001]/items[at0002]"
          }
        }
      }
    },
    "rules": {
      "gt0009": {
        "id": "gt0009",
        "priority": 8,
        "when": [
          "$gt0007|Breast cancer stage|==0|local::at0036|Stage 0|"
        ],
        "then": [
          "$gt0005|5 Year Survival rates|=0|local::at0003|99% Stage 0|"
        ]
      },
      "gt0010": {
        "id": "gt0010",
        "priority": 7,
        "when": [
          "($gt0007|Breast cancer stage|==1|local::at0037|Stage IA|)||($gt0007|Breast cancer stage|==2|local::at0038|Stage IB|)"
        ],
        "then": [
          "$gt0005|5 Year Survival rates|=1|local::at0004|92% Stage I|"
        ]
      },
      "gt0011": {
        "id": "gt0011",
        "priority": 6,
        "when": [
          "$gt0007|Breast cancer stage|==3|local::at0039|Stage IIA|"
        ],
        "then": [
          "$gt0005|5 Year Survival rates|=2|local::at0005|82% Stage IIA|"
        ]
      },
      "gt0012": {
        "id": "gt0012",
        "priority": 5,
        "when": [
          "$gt0007|Breast cancer stage|==4|local::at0040|Stage IIB|"
        ],
        "then": [
          "$gt0005|5 Year Survival rates|=3|local::at0006|65% Stage IIB|"
        ]
      },
      "gt0013": {
        "id": "gt0013",
        "priority": 4,
        "when": [
          "$gt0007|Breast cancer stage|==5|local::at0041|Stage IIIA|"
        ],
        "then": [
          "$gt0005|5 Year Survival rates|=4|local::at0007|47% Stage IIIA|"
        ]
      },
      "gt0014": {
        "id": "gt0014",
        "priority": 3,
        "when": [
          "$gt0007|Breast cancer stage|==6|local::at0042|Stage IIIB|"
        ],
        "then": [
          "$gt0005|5 Year Survival rates|=5|local::at0008|44% Stage IIIB|"
        ]
      },
      "gt0015": {
        "id": "gt0015",
        "priority": 2,
        "when": [
          "$gt0007|Breast cancer stage|==7|local::at0043|Stage IIIC|"
        ],
        "then": [
          "$gt0005|5 Year Survival rates|=6|local::at0009|14-44% Stage IIIc|"
        ]
      },
      "gt0016": {
        "id": "gt0016",
        "priority": 1,
        "when": [
          "$gt0007|Breast cancer stage|==8|local::at0044|Stage IV|"
        ],
        "then": [
          "$gt0005|5 Year Survival rates|=7|local::at0010|14% Stage IV|"
        ]
      }
    }
  },
  "ontology": {
    "term_definitions": {
      "sv": {
        "id": "sv",
        "terms": {
          "gt0001": {
            "id": "gt0001",
            "text": "TNM bröstcancer - utvärdering",
            "description": "American Joint Committee on Cancers (AJCC) TNM-klassifikation beskriver allvarlighetsgrad av bröstcancer baserat på tumörstorlek, lymfkörtelengagemang och förekomst av metastaser."
          },
          "gt0005": {
            "id": "gt0005",
            "text": "5-årsöverlevnad",
            "description": "5-årsöverlevnad baserat på stadieindelning."
          },
          "gt0006": {
            "id": "gt0006",
            "text": "Stadium - bröstcancer",
            "description": "TNM-klassifikation med stadieindelning av bröstcancer"
          },
          "gt0007": {
            "id": "gt0007",
            "text": "Stadium - bröstcancer",
            "description": "TNM-klassifikation med stadieindelning av bröstcancer"
          },
          "gt0008": {
            "id": "gt0008",
            "text": "CDS stadium"
          },
          "gt0009": {
            "id": "gt0009",
            "text": "Stadium 0 - 5-årsöverlevnad"
          },
          "gt0010": {
            "id": "gt0010",
            "text": "Stadium I - 5-årsöverlevnad"
          },
          "gt0011": {
            "id": "gt0011",
            "text": "Stadium IIA - 5-årsöverlevnad"
          },
          "gt0012": {
            "id": "gt0012",
            "text": "Stadium IIB - 5-årsöverlevnad"
          },
          "gt0013": {
            "id": "gt0013",
            "text": "Stadium IIIA  - 5-årsöverlevnad"
          },
          "gt0014": {
            "id": "gt0014",
            "text": "Stadium IIIB  - 5-årsöverlevnad"
          },
          "gt0015": {
            "id": "gt0015",
            "text": "Stadium IV  - 5-årsöverlevnad"
          },
          "gt0016": {
            "id": "gt0016"
          },
          "gt0017": {
            "id": "gt0017"
          },
          "gt0019": {
            "id": "gt0019"
          },
          "gt0020": {
            "id": "gt0020",
            "text": "*(en) Event time",
            "description": "*(en) The exact time of a single timed event during the Observation. Can represent either a specific point-in-time or an interval event."
          }
        }
      },
      "en": {
        "id": "en",
        "terms": {
          "gt0001": {
            "id": "gt0001",
            "text": "TNM Breast Assessment",
            "description": "The American Joint Committee on Cancer (AJCC) TNM staging system reports on the severity of breast cancer based on tumor, lymph node and metastasis characteristics."
          },
          "gt0005": {
            "id": "gt0005",
            "text": "5 Year Survival rates",
            "description": "5 Year survival according to the Stage of breast cancer"
          },
          "gt0006": {
            "id": "gt0006",
            "text": "Breast cancer stage",
            "description": "Breast cancer staging made up of the TNM groups"
          },
          "gt0007": {
            "id": "gt0007",
            "text": "Breast cancer stage",
            "description": "Breast cancer staging made up of the TNM groups"
          },
          "gt0008": {
            "id": "gt0008",
            "text": "set staging"
          },
          "gt0009": {
            "id": "gt0009",
            "text": "Stage 0 - 5 year survival"
          },
          "gt0010": {
            "id": "gt0010",
            "text": "Stage I - 5 year survival"
          },
          "gt0011": {
            "id": "gt0011",
            "text": "Stage IIA - 5 year survival"
          },
          "gt0012": {
            "id": "gt0012",
            "text": "Stage IIB - 5 year survival"
          },
          "gt0013": {
            "id": "gt0013",
            "text": "Stage IIIA  - 5 year survival"
          },
          "gt0014": {
            "id": "gt0014",
            "text": "Stage IIIB  - 5 year survival"
          },
          "gt0015": {
            "id": "gt0015",
            "text": "Stage IIIC  - 5 year survival"
          },
          "gt0016": {
            "id": "gt0016",
            "text": "Stage IV - 5 year survival"
          },
          "gt0017": {
            "id": "gt0017",
            "text": "stage"
          },
          "gt0019": {
            "id": "gt0019",
            "text": "Breast cancer stage",
            "description": "Breast cancer staging made up of the TNM groups"
          },
          "gt0020": {
            "id": "gt0020",
            "text": "Event time",
            "description": "The exact time of a single timed event during the Observation. Can represent either a specific point-in-time or an interval event."
          }
        }
      }
    }
  }
}